HLA antibodies in pediatric heart transplantation

Pediatr Transplant. 2011 Aug;15(5):458-64. doi: 10.1111/j.1399-3046.2010.01435.x. Epub 2011 Mar 30.

Abstract

We have analyzed the impact of anti-HLA antibodies present in the patients' circulation prior and/or following heart transplantation in a population of 108 pediatric recipients. Anti-HLA class I and class II antibodies were monitored by traditional CDC using donor and panel T and B lymphocytes and by SPA for detection of DSA. There was a highly significant correlation between the development of AMR and presence of CDC- or SPA-detected DSA. However, the fraction of the transplant population which remained AMR-free was much higher among patients with SPA-detected compared to CDC-detected DSA. Furthermore, long-term graft survival was negatively affected only by cytotoxic, complement-fixing anti-HLA class I antibodies developing following transplantation. Anti-HLA class I or class II antibodies detected by SPA had no effect on long-term survival rates.

MeSH terms

  • Adolescent
  • Antibodies / chemistry*
  • B-Lymphocytes / immunology
  • Biopsy
  • Child
  • Child, Preschool
  • Complement System Proteins
  • Endocardium / pathology
  • Female
  • Heart Failure / therapy*
  • Heart Transplantation / methods*
  • Histocompatibility Antigens Class I / immunology*
  • Histocompatibility Antigens Class II / immunology*
  • Humans
  • Immunophenotyping
  • Infant
  • Infant, Newborn
  • Male
  • Myocardium / pathology
  • Pediatrics
  • Time Factors
  • Treatment Outcome

Substances

  • Antibodies
  • Histocompatibility Antigens Class I
  • Histocompatibility Antigens Class II
  • Complement System Proteins